An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency
Thrombosis and Haemostasis · 01.03.2025 · 125 (03) · 207-217
DOI: 10.1055/a-2373-2829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2025. Verfasst von Claire Auditeau und 11 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Hémostase inflammation thrombose HITh U1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Hemophilia A, Thrombin, Serpins, Factor XI Deficiency. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Protein Z-dependent protease inhibitor (ZPI) is an anticoagulant serpin that targets factor Xa (FXa) in the presence of protein Z (PZ), and factor XIa (FXIa). In factor-VIII-deficient mice, PZ or ZPI gene knock-out mitigates the bleeding phenotype, and pharmacological inhibition of PZ enhances thrombin generation in plasma from patients with hemophilia.
Aims
To develop a single-domain antibody (sdAb) directed against ZPI to inhibit its anticoagulant activity.
Methods
We screened for anti-ZPI sdAbs in a llama-derived phage display immune library of sdAbs. The sdAbs that bound ZPI were produced and purified for characterization. The binding of sdAbs to ZPI or other serpins was evaluated using ELISAs, and ZPI inhibition was measured in an anti-FXa or anti-FXIa chromogenic assay. The sdAbs's procoagulant activity was assessed in a thrombin generation assay in normal plasma, factor VIII- and FXI-deficient plasma.
Results
Of the four sdAbs found to bind to ZPI, one (referred to as ZPI-sdAb2) dose-dependently inhibited ZPI's anti-FXa and anti-FXIa activities with a mean half-maximal inhibitory concentration of 1.8 and 1.3 µM, respectively. ZPI-sdAb2 did not cross-react with other plasma serpins, such as antithrombin and α1-antitrypsin. ZPI-sdAb2 induced a significant increase in thrombin generation in plasma samples from healthy donors, patients with severe hemophilia A, and patients with FXI deficiency.
Conclusion
ZPI-sdAb2 is the first specific, direct ZPI inhibitor found to exhibit procoagulant activity in plasma. This sdAb might have potential as a treatment for hemophilia or other bleeding disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- INSERM, Hémostase inflammation thrombose HITh U1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
- Service d'Hématologie Biologique, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- Laboratoire d'Hématologie Biologique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Faculté de médecine, université Paris Saclay, Le Kremlin-Bicêtre, France.
ORCID-Profile: Elsa P Bianchini
Zitieren
APA
Auditeau, C., Nguyen, T. S., Devaux, F., Saller, F., Peyron, I., Blandinières, A., Repérant, C., Daramé, S., Denis, C. V., Lenting, P., Borgel, D., & Bianchini, E. P. (2025). An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency. Thrombosis and Haemostasis, 125(03), 207-217. https://doi.org/10.1055/a-2373-2829
Vancouver
Auditeau C, Nguyen TS, Devaux F, Saller F, Peyron I, Blandinières A, et al. An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency. Thrombosis and Haemostasis. 2025;125(03):207-217. doi:10.1055/a-2373-2829
BibTeX
@article{Auditeau2025,
author = {Auditeau, Claire and Nguyen, Tung-Son and Devaux, Floriane and Saller, François and Peyron, Ivan and Blandinières, Adeline and Repérant, Christelle and Daramé, Sadyo and Denis, Cécile V and Lenting, Peter and Borgel, Delphine and Bianchini, Elsa P},
title = {An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {03},
pages = {207--217},
doi = {10.1055/a-2373-2829}
}
EUVIMED